Log In Sign up
The largest database of trusted experimental protocols

Ceritinib

Manufactured by Active Motif
Visit Supplier
Sourced in Hong Kong, China

Ceritinib is a lab equipment product developed by Active Motif. It is a small-molecule inhibitor that targets the ALK (anaplastic lymphoma kinase) protein.

Automatically generated - may contain errors

Lab products found in correlation

Alectinib, by Active Motif (6 mentions) Cabozantinib, by Active Motif (3 mentions) Foretinib, by Adooq (2 mentions) Lorlatinib, by Active Motif (2 mentions) Kanamycin, by Meiji Seika Pharma (1 mentions) Fetal bovine serum (fbs), by Thermo Fisher Scientific (1 mentions) Dimethyl sulfoxide (dmso), by Merck Group (1 mentions) Gentamicin, by Thermo Fisher Scientific (1 mentions) Alectinib, by Selleck Chemicals (1 mentions) Crizotinib, by Selleck Chemicals (1 mentions) Asp3026, by Chemietek (1 mentions) Nvp tae 684, by Chemietek (1 mentions) Ap26113, by Selleck Chemicals (1 mentions) 17 aag, by LC Laboratories (1 mentions) Trametinib, by Adooq (1 mentions) Amg510, by MedChemExpress (1 mentions) Sb202190, by Cell Signaling Technology (1 mentions) Trametinib, by Active Motif (1 mentions) Sb239063, by Merck Group (1 mentions) Tae684, by Chemietek (1 mentions)

8 protocols using ceritinib

1

EML4-ALK Variants and Inhibitor Impacts

Check if the same lab product or an alternative is used in the 5 most similar protocols
Ba/F3 immortalized murine bone marrow‐derived pro‐B cells were cultured with Dulbecco's modified Eagle medium (DMEM) low glucose supplemented with 10% fetal bovine serum (FBS) and kanamycin (250 mg/mL; Meiji Seika Pharma, Tokyo, Japan) and 0.5 ng/mL of interleukin‐3 (IL‐3). Human kidney embryo cell lines, 293FT cells were cultured in DMEM high glucose with 10% FBS. The cells were infected with lentivirus replicated in 293FT cells by transforming them with paging plasmids (Virapower), which express rearranged cDNA regions encoding EML4‐ALK variant 1 and either WT or different mutations (I1171S and I1171S + G1269A). Cells were selected with blasticidin (7 μg/mL) for one week. After selection, IL‐3 was withdrawn from the culture medium.
Crizotinib (PF‐02341066), lorlatinib (PF‐06463922), and brigatinib (AP26113) were obtained from Shanghai Biochempartner (Shanghai, China). Alectinib (CH5424802), and ceritinib (LDK‐378) was purchased from ActiveBiochem (Hong Kong).
Takahashi K., Seto Y., Okada K., Uematsu S., Uchibori K., Tsukahara M., Oh‐hara T., Fujita N., Yanagitani N., Nishio M., Okubo K, & Katayama R. (2020). Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer. Thoracic Cancer, 11(3), 581-587.
+ Open protocol
+ Expand
2

Establishment of ALK Inhibitor-Resistant Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
NCI-H3122 cells were provided by Pasi A. Jänne (DanaFarber Cancer Institute, Boston, MA). H3122 cells were maintained in RPMI 1640 medium with gentamicin (Gibco, Grand Island, NY) and supplemented with 10% fetal bovine serum (Gibco). The cell line was incubated at 37°C in a humidified atmosphere of 5% carbon dioxide. Crizotinib and alectinib were purchased from Selleck Chemicals (Houston, TX) and dissolved in dimethyl sulfoxide (Sigma-Aldrich, St. Louis, MO) for experiments. Ceritinib was obtained from Active Biochem (Maplewood, NJ). ALK inhibitor-resistant cell lines (CR1, LR1, and CH1) were established by exposing parental H3122 cells to Crizotinib, Ceritinib (LDK378), and alectinib (CH-5424802), respectively, at doses of 100 nM to 1 μM. Double-resistant cell lines (CR1LR1 and CR1CH1) were generated by exposing the Crizotinib-resistant cell line CR1 to Ceritinib and alectinib, respectively. The subclonal resistant cell lines exhibited ≥ 5-fold greater IC50 values for ALK inhibitors than parental cells, as determined using the cell viability assay, and this phenotype was stable for at least 6 months without ALK inhibitor treatment.
Kim S.J., Kim S., Kim D.W., Kim M., Keam B., Kim T.M., Lee Y., Koh J., Jeon Y.K, & Heo D.S. (2018). Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Research and Treatment : Official Journal of Korean Cancer Association, 51(3), 1231-1240.
+ Open protocol
+ Expand
3

Inhibitor Screening for Cancer Research

Check if the same lab product or an alternative is used in the 5 most similar protocols
Crizotinib was obtained from ShangHai Biochempartner (ShangHai, China); alectinib, cabozantinib, and ceritinib (LDK378) were purchased from ActiveBiochem (Hong Kong), 17-AAG was purchased from LC Laboratories (Woburn, MA, USA); NVP-TAE-684 and ASP3026 were purchased from ChemieTek (Indianapolis, IN, USA); AP26113 was purchased from Selleck (Cambridge, MA); and Foretinib was purchased from AdooQ BioScience (Irvine, CA, USA). Each compound was dissolved in dimethyl sulfoxide (DMSO) for cell culture experiments. For inhibitor screening, the SCADS Inhibitor kit was provided by the Screening Committee of Anticancer Drugs supported by a Grant-in-Aid for Scientific Research on Innovative Areas, Scientific Support Programs for Cancer Research, from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.
Katayama R., Kobayashi Y., Friboulet L., Lockerman E.L., Koike S., Shaw A.T., Engelman J.A, & Fujita N. (2014). Cabozantinib overcomes crizotinib resistance in ROS1 fusion positive cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 21(1), 166-174.
+ Open protocol
+ Expand
4

ALK Inhibitor Compounds Procurement

Check if the same lab product or an alternative is used in the 5 most similar protocols
Crizotinib (PF-02341066), brigatinib (AP26113), and lorlatinib (PF-06463922) were purchased from Shanghai Biochempartner (Shanghai, Chaina). Gilteritinib (ASP2215) was purchased from Shanghai Biochempartner and Biovision (Milpitas, CA, USA). Alectinib (CH5424802) and ceritinib (LDK378) were purchased from ActiveBiochem (Kowloon, Hong Kong). Entrectinib (RXDX-101) and AMG510 were purchased from Medchem Express (Monmouth Junction, NJ, USA). Afatinib (BIBW2992) was purchased from ChemieTek (Indianapolis, IN, USA). Trametinib (GSK1120212) was purchased from AdooQ BioScience (Irvine, CA, USA). Brigatinib was dissolved in ethanol for in vitro experiments, and the other drugs were dissolved in dimethyl sulfoxide (DMSO).
Mizuta H., Okada K., Araki M., Adachi J., Takemoto A., Kutkowska J., Maruyama K., Yanagitani N., Oh-hara T., Watanabe K., Tamai K., Friboulet L., Katayama K., Ma B., Sasakura Y., Sagae Y., Kukimoto-Niino M., Shirouzu M., Takagi S., Simizu S., Nishio M., Okuno Y., Fujita N, & Katayama R. (2021). Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. Nature Communications, 12, 1261.
+ Open protocol
+ Expand
5

Compound Acquisition for Cell Experiments

Check if the same lab product or an alternative is used in the 5 most similar protocols
Crizotinib (PF-02341066) was obtained from ShangHai Biochempartner; cabozantinib (XL184), ceritinib (LDK378), lorlatinib (PF-06463922), trametinib (GSK1120212) from ActiveBiochem; foretinib from AdooQ Bioscience; brigatinib from Sellek; radicicol and rotenone from Cayman Chemical; 17-AAG (17-N-Allylamino-17-demethoxygeldanamycin) and GDC-0941 from LC Laboratories; TAE684 from ChemieTek; SB202190 from Cell Signaling Technology; SB239063 from Sigma; and cycloheximide and doxycycline hyclate from Nacalai Tesque. Each compound was prepared in dimethyl sulfoxide (DMSO), ethanol (WAKO) or distilled water for cell culture experiments.
Ogura H., Nagatake-Kobayashi Y., Adachi J., Tomonaga T., Fujita N, & Katayama R. (2017). TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity. Scientific Reports, 7, 5519.
+ Open protocol
+ Expand
6

Small Molecule Inhibitor Panel

Check if the same lab product or an alternative is used in the 5 most similar protocols
Ceritinib, alectinib, lorlatinib, cabozantinib, and zoligratinib were purchased from ActiveBiochem. Crizotinib, brigatinib, and infigratinib were purchased from Biochempartner. AZD4547 was purchased from Selleck, and PHA665752 was purchased from Tocris Bioscience.
Sakashita T., Yanagitani N., Koike S., Low S., Takagi S., Baba S., Takeuchi K., Nishio M., Fujita N, & Katayama R. (2022). Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK‐rearranged non–small cell lung cancer. Cancer Science, 113(11), 3888-3900.
+ Open protocol
+ Expand
7

Sourcing and Prepping Kinase Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lorlatinib, crizotinib, and brigatinib were purchased from ShangHai Biochempartner (Shanghai, China); alectinib and ceritinib from ActiveBiochem (Kowloon, Hong Kong); and dasatinib from SelleckChem (Houston, TX, USA). LY2090314 was purchased from AdooQ BioScience (Irvine, CA, USA) and TWS119 from Santa Cruz Biotechnology (Dallas, TX, USA). Brigatinib was dissolved in ethanol, and the other inhibitors were dissolved in dimethyl sulfoxide (DMSO) for cell culture experiments. Details of the other inhibitors for focused inhibitor library screening are shown in Supplementary Table 1.
Shimizu Y., Okada K., Adachi J., Abe Y., Narumi R., Uchibori K., Yanagitani N., Koike S., Takagi S., Nishio M., Fujita N, & Katayama R. (2022). GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer. NPJ Precision Oncology, 6, 16.
+ Open protocol
+ Expand
8

Synthesis of Kinase Inhibitor Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols
DS-6051b, crizotinib, lorlatinib (PF-06463922), and entrectinib were synthesized at DaiichiSankyo Co. Ltd. (Tokyo, Japan). Synthetic scheme of DS-6051b was described in Supplementary Fig. 11. Cabozantinib and brigatinib (AP26113) were purchased from ShangHai Biochempartner (Shanghai, China). Alectinib and ceritinib were purchased from ActiveBiochem (Hong Kong). Each compound was dissolved in dimethyl sulfoxide (DMSO) for the cell culture experiments.
Katayama R., Gong B., Togashi N., Miyamoto M., Kiga M., Iwasaki S., Kamai Y., Tominaga Y., Takeda Y., Kagoshima Y., Shimizu Y., Seto Y., Oh-hara T., Koike S., Nakao N., Hanzawa H., Watanabe K., Yoda S., Yanagitani N., Hata A.N., Shaw A.T., Nishio M., Fujita N, & Isoyama T. (2019). The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nature Communications, 10, 3604.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!